Welcome to our dedicated page for SAB BIOTHERAPEUTICS news (Ticker: SABS), a resource for investors and traders seeking the latest updates and insights on SAB BIOTHERAPEUTICS stock.
SAB Biotherapeutics, Inc. (Nasdaq: SABS), or SAB BIO, generates frequent news as a clinical-stage biopharmaceutical company advancing fully human immunoglobulin G (hIgG) and human anti-thymocyte immunoglobulin (hATG) therapies for immune and autoimmune disorders. Most recent headlines focus on SAB-142, the company’s multi-specific, fully human anti-thymocyte globulin in development as a potentially disease-modifying, redosable immunotherapy for autoimmune type 1 diabetes (T1D) in new-onset, Stage 3 patients.
News updates commonly cover clinical milestones for SAB-142, including Phase 1 trial results and the launch and progress of the Phase 2b registrational SAFEGUARD study. Releases describe safety, pharmacodynamic, and immunogenicity findings, such as the absence of serum sickness and anti-drug antibodies in the Phase 1 trial, as well as the design and enrollment status of the SAFEGUARD trial at multiple centers around the world.
SABS news also highlights SAB BIO’s scientific presence at major medical meetings. The company regularly announces oral and poster presentations at conferences such as the European Association for the Study of Diabetes (EASD), the International Society for Pediatric and Adolescent Diabetes (ISPAD), and the Asian Conference on Innovative Therapies for Diabetes Management. These items detail new data on SAB-142’s mechanism of action, immunomodulatory effects without sustained lymphodepletion, and pharmacokinetic profiling.
Investors and observers will also find corporate and investor-relations updates, including participation in healthcare investor conferences and changes to the Board of Directors, as well as summaries of quarterly financial results and business highlights. For anyone tracking SABS, this news feed provides an ongoing view into SAB BIO’s clinical development progress, scientific communications, governance developments, and key events related to its lead program SAB-142 and its broader human IgG platform.
SAB Biotherapeutics (NASDAQ: SABS) announced a Virtual 2022 Annual R&D Portfolio Update on August 17, 2022, at 10:30 a.m. ET. The update will showcase the company's unique DiversitAb™ immunotherapy platform that produces high-potency, fully-human polyclonal antibodies without human donors. Executives will discuss planned clinical and preclinical development programs targeting diseases like COVID-19 and type 1 diabetes. A live webcast will be available, with a replay on the company's website. For registration details, visit www.sab.bio.
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Rear Admiral Scott Giberson to its Board of Directors, effective July 7, 2022. Giberson, a retired two-star admiral with extensive government and healthcare experience, will bring valuable insights to the company. His previous roles include Deputy Surgeon General and Commander of the Commissioned Corps’ Ebola Response. SAB aims to leverage Giberson’s expertise to address unmet medical needs through its innovative immunotherapy platform. The company focuses on developing fully human polyclonal antibodies targeting diseases like COVID-19 and type 1 diabetes.
SAB Biotherapeutics (SABS) hosted Congressmen Dusty Johnson and Dean Phillips on July 1, 2022, at its Sioux Falls facility. The visit showcased SAB's innovative immunotherapy platform that produces fully human polyclonal antibodies through genetically engineered cattle. The Congressmen engaged with SAB's management team, discussing advancements in COVID-19 treatment and the company's pipeline targeting influenza, oncology, and type 1 diabetes. SAB aims to address unmet global health needs with its DiversitAb™ platform.
SAB Biotherapeutics (Nasdaq: SABS) announced the appointment of Dr. Alexandra Kropotova as Chief Medical Officer to enhance its pipeline in immune and autoimmune disorders. With over 20 years of experience, Dr. Kropotova previously led drug development at Teva Pharmaceuticals and has held key roles at Sanofi and Pfizer. Her expertise is expected to be vital for advancing SAB's initiatives in areas such as infectious diseases and cancer. The company continues to leverage its innovative platform for producing high-potency, fully human polyclonal antibodies.
SAB Biotherapeutics will present at the Large Animal Genetic Engineering Summit on June 7, 2022, in Park City, Utah. CEO Dr. Christoph Bausch will discuss advancements in their Transchromosomic (Tc) Goat platform for producing fully human polyclonal antibodies. The presentation will cover the DiversitAb platform, highlighting pipeline programs including SAB-185 (anti-SARS-CoV-2), SAB-176 (influenza), and SAB-142 (Type 1 diabetes). The company focuses on innovative immunotherapy solutions aimed at serious diseases.
SAB Biotherapeutics (Nasdaq: SABS) reported its Q1 2022 financial results and company updates, emphasizing significant advancements in its immunotherapy platform.
Key highlights include:
- Cash and cash equivalents of $22.4 million as of March 31, 2022.
- R&D expenses increased to $13.3 million, attributed to expanded capabilities.
- Net income was $1 million, equating to $0.02 per share.
Full data from the Phase 2a trial for SAB-176 is expected in Q3 2022, with additional updates on SAB-185 and other pipeline candidates anticipated later this year.
SAB Biotherapeutics (NASDAQ: SABS) will participate in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company's management team is scheduled for a live Fireside Chat on May 25, 2022, at 9:00 am EDT. An on-demand webcast will be available on their website, allowing investors to access the presentation for 90 days post-event. SAB Biotherapeutics focuses on developing immunotherapies using fully human polyclonal antibodies for various diseases, including COVID-19 and type 1 diabetes.
SAB Biotherapeutics has appointed Dr. Mark J. Ratain to its Board of Scientific Advisors to enhance its oncology platform. Dr. Ratain, a prominent expert in cancer treatment and clinical pharmacology, has published over 500 academic works and will contribute his extensive knowledge to advance SAB's fully-human polyclonal antibody therapies.
CEO Eddie J. Sullivan expressed enthusiasm about Dr. Ratain's addition, emphasizing the potential benefits for the company’s targeted multivalent immunotherapies aimed at treating cancer.
SAB Biotherapeutics reported significant progress in 2021, highlighted by the closing of its business combination and listing on NASDAQ. The company is advancing its pipeline of polyclonal antibodies, including SAB-185 for COVID-19 and SAB-176 for influenza, with initial data expected mid-2022. SAB's Rapid Response Antibody Program, in collaboration with the US Department of Defense, is also ongoing. With cash reserves of $33.2 million and additional government funding expected, SAB anticipates sufficient resources to support operations through Q3 2023.
SAB Biotherapeutics announced the discontinuation of patient enrollment in the NIH’s ACTIV-2 Phase 3 COVID-19 trial due to low hospitalization and death rates, which rendered the study statistically unworkable. Despite SAB-185 achieving pre-specified efficacy and safety criteria, the Data and Safety Monitoring Board deemed it operationally futile to continue the study. SAB Biotherapeutics is now exploring future clinical plans for SAB-185, targeting high-risk populations for prophylactic and therapeutic applications.